UNSPSC 51151512: Neostigmine

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C12H19N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3982TWQ96G, chemically known as 3-trimethylammoniumphenyl n,n-dimethylcarbamate but generally known as neostigmine, which bears US NIH Compound Identifier 4456. European Medicines Agency schedules Neostigmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03411MIG.

UNSPSC 51151512 Neostigmine is a Commodity code that in recent state and local activity covers pharmaceutical procurement, though the sourced opportunities show a significant mismatch with the code's nominal scope. Seminole County, Florida issued IFB 60459723LAS seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building, a competitive bid process distinct from neostigmine. The Texas Health and Human Services Commission issued RFI HHS0017013 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models between state pharmacy benefit programs and manufacturers to improve fulfillment efficiency and cost management. Both opportunities reflect state and county health agencies procuring pharmaceuticals and drug-related services, but neither directly addresses neostigmine or its clinical use.

The issuing bodies include county health departments and state health and human services commissions pursuing these procurements. Geographic activity appears concentrated in Florida and Texas based on the recent record. Seminole County's IFB closed July 26, 2023, with electronic submission required through the county's e-Procurement Portal and a two-year initial term with one-year renewal option; vendors must meet E-Verify compliance, drug-free workplace certification, and specified insurance coverages including workers' compensation and professional liability. The Texas HHS Commission's RFI posted April 3, 2026, with the same response deadline, sought information from vendors with direct-contracting experience serving self-insured employers and government health plans in the preceding two years. The code shows limited recent activity directly aligned with neostigmine procurement; opportunities posted under this code nominally involve broader pharmaceutical and drug-management services rather than this specific cholinesterase inhibitor.